Brain scans reveal Ocrelizumab's impact on MS inflammation
NCT ID NCT04230174
First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 23 times
Summary
This study looked at how the drug ocrelizumab changes brain inflammation in people with multiple sclerosis (MS). Twenty-two adults with MS had special brain scans before and after one year of treatment. The goal was to see if ocrelizumab reduces inflammation in different brain areas. Results help doctors understand how the drug works to control MS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Charlestown, Massachusetts, 02129, United States
Conditions
Explore the condition pages connected to this study.